Dermabond Landing page_Oct 2022 V1.png

Meet the DERMABOND® Family
THE WORLD’S MOST TRUSTED WOUND CLOSURE PRODUCTS

DERMABOND® is a precisely balanced formulation unlike any other TSA on the market
Our proprietary formulation is a precisely balance combination of three carefully sourced components. There is no other brand with the same formula.

EHC-Dermabond-Landing-Page-Material_Oct-20222-kr1.png

Topical skin adhesives (TSAs) are an integral part of a successful clinical outcome.
When deciding which TSA to use, clinical study information on closure strength, microbial protection, patient comfort, and cosmesis allows healthcare practitioners to evaluate which product will provide the greatest benefits for their patients.

DERMABOND® Skin Adhesives is backed by an extensive body of published literature that has been shown to provide superior strength verses other commercially available TSA’s and also has benefits that enhance patient comfort and cosmetic outcomes.

EHC AU Dermabond Results graphs_Nov 2022.png

Fortify your skin closure in 3 ways and achieve improved patient outcomes

Strengthens

  • When used in addition to sutures, DERMABOND Topical Skin Adhesive was shown ex vivo to add 75% more strength to the wound closure than sutures alone.

Inhibits Bacteria

  • DERMABOND Topical Skin Adhesive demonstrated in vitro inhibition of gram positive bacteria (MRSA and MRSE) and gram negative bacteria (E.Coli) for 48 hours± 2 Provides a Microbial Barrier

Provides a Microbial Barrier

  • DERMABOND Topical Skin Adhesive provides a flexible microbial barrier with >99% protection in vitro for at least 72 hours against organisms commonly responsible for SSIs2

DERMABOND® Mini Topical Skin Adhesive

EHC-Dermabond-Landing-Page-Material_Oct-20226---KR.png

A protective barrier that adds strength and inhibits bacteria

  • Provides a microbial barrier with 99% protection in vitro for 72 hours against organisms commonly responsible for SSIs2
  • Demonstrates inhibition of gram-positive bacteria (MRSA and MRSE) and gram-negative bacteria (E coli) in vitro

Unique formulation with additional value

  • Addresses cost and convenience concerns by eliminating the need for return visits to remove suture
  • Offers fast closure of small incisions and lacerations
  • Provides patient comfort by providing flexible closure without the pain or anxiety caused by needles

Click here to learn more about Dermabond Mini

DERMABOND® ADVANCED™ Topical Skin Adhesive

Designed for easy use and application

EHC-Dermabond-Landing-Page-Material_Oct-20223-KR.png

Patient Comfort & Satisfaction

  • In a prospective randomised study of minimally invasive vein harvest closure in 106 patients surgeries, patient satisfaction, colour and visibility of scar was significantly better with Dermabond® Adhesive at 6 weeks 
  • In a retrospective study of bilateral mammoplasties in 670 patients, patient comfort and satisfaction were also superior with DERMABOND® Adhesive
  • Patients can shower immediately as directed by their physician

Reduced Incidence of SSIs

  • After CABG surgery, the incidence of SSIs was reduced by 57% for wounds closed with DERMABOND® Adhesive in addition to sutures, compared to wounds closed with sutures alone

Decreased Length of Stay

  • The use of DERMABOND® Adhesive in CABG surgery was associated with allowing patients to return home 4 days earlier (9 days stay, instead of 13) 

DERMABOND® PRINEO® Skin Closure System

EHC-Dermabond-Landing-Page-Material_Oct-20225-kr.png

A combination of 2-octyl cyanoacrylate (2-OCA) and a self-adhering mesh

Protection

  • Provides microbial-barrier protection 99% effective in vitro for 72 hours against organisms commonly responsible for surgical site infection (SSI)2
  • Demonstrates in vitro inhibition of bacteria (Methicillin-resistant Staphylococcus aureus, Methicillin-resistant Staphylococcus epidermidis, Escherichia coli)

Strength

  • Significantly greater skin holding strength than skin staples or subcuticular suture
  • Redistributes tension away from the wound to the surrounding healthy surface area

Patient Satisfaction

  • Patient may be able to shower immediately after the procedure, if directed by the healthcare professional
  • At the time of removal, DERMABOND® PRINEO® System is associated with less pain than other wound closure devices
  • No post-surgical dressings may mean easier selfcare and greater self-confidence for patients

 

DERMABOND® PRINEO® family continues to grow, offering a closure solution for more surgical wounds - (22cm, 42cm and 60cm)

 

EHC Dermabond Prineo Landing page elements_Nov 2022.png

DERMABOND PRINEO System combinesthe proven strength, ­flexibility, and antimicrobial protection of DERMABOND ADVANCED® Topical Skin Adhesive with the added support and security of a self-adhering mesh to further facilitate both wound-edge approximation and an optimal healing environment4.

Shown to provide statistically significant greater skin-holding strength than skin staples or subcuticular suture.

EHC Dermabond Prineo Landing page elements_Nov 20222.png

Buy the DERMABOND® family today

DERMABOND ADVANCED Topical Skin Adhesive 7ml - Box/12

DERMABOND ADVANCED Topical Skin Adhesive 7ml - Box/12

DERMABOND® Mini Topical Skin Adhesive .36mL Amps - Box/12

DERMABOND® Mini Topical Skin Adhesive .36mL Amps - Box/12

DERMABOND® PRINEO® Topical Skin Adhesive 22cm - Box/2

DERMABOND® PRINEO® Topical Skin Adhesive 22cm - Box/2

DERMABOND® PRINEO® Violet Skin Closure System 42CM - Box/2

DERMABOND® PRINEO® Violet Skin Closure System 42CM - Box/2

DERMABOND® PRINEO® Skin Closure System 60cm - Box/2

DERMABOND® PRINEO® Skin Closure System 60cm - Box/2

Request More Information

Please fill in the form below to request more information and/or free samples of Dermabond products.

Request Multiple choice

EBOS Group Australia Pty Ltd (EBOS Healthcare) collects your personal information (PI) for the purposes of responding to your query, including to provide you with information about EBOS Healthcare’s products and services.  For these purposes, EBOS Healthcare may disclose your PI to our related bodies corporate and third parties contracted to us. If you do not provide this information, we may not be able to respond to your query. Our Privacy Policy contains further information on how we collect, hold and use your PI.

I consent to my information being collected and have read and understood the Privacy Policy

References: 

  1. Data on file. Ethicon Inc. Report: Protocol to determine the strength benefits when adding Dermabond Advanced Topical Skin Adhesive to wound using suture as the primary closure. 2011 
  2. Bhende S, et al in Vitro Assessment of Microbial Barrier properties of Dermabond, Topical skin Adhesive, Surgical Infections, 2002,3,251-257 
  3. Bhende S, Rothenburger S, Spangler DJ, Ditto M, In Vitro assessment of microbial barrier properties of Dermabond Topical skin adhesive. Surg Infect 2002;3(3) 251-257 
  4. Dermabond Prineo Skin Closure System (22cm ) instructions for use Ethicon Inc.